Han Yu Jin, Jang Wonjin, Kim Jung Sun, Kim Hyun Jeong, Suh Sung Yun, Cho Yoon Sook, Park June Dong, Lee Bongjin
Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea.
Department of Pediatrics, Seoul National University Hospital and College of Medicine, Seoul 03080, Korea.
Korean J Physiol Pharmacol. 2024 Mar 1;28(2):121-127. doi: 10.4196/kjpp.2024.28.2.121.
Vancomycin is a frequently used antibiotic in intensive care units, and the patient's renal clearance affects the pharmacokinetic characteristics of vancomycin. Several advantages have been reported for vancomycin continuous intravenous infusion, but studies on continuous dosing regimens based on patients' renal clearance are insufficient. The aim of this study was to develop a vancomycin serum concentration prediction model by factoring in a patient's renal clearance. Children admitted to our institution between July 1, 2021, and July 31, 2022 with records of continuous infusion of vancomycin were included in the study. Sex, age, height, weight, vancomycin dose by weight, interval from the start of vancomycin administration to the time of therapeutic drug monitoring sampling, and vancomycin serum concentrations were analyzed with the linear regression analysis of the mixed effect model. Univariable regression analysis was performed using the vancomycin serum concentration as a dependent variable. It showed that vancomycin dose (p < 0.001) and serum creatinine (p = 0.007) were factors that had the most impact on vancomycin serum concentration. Vancomycin serum concentration was affected by vancomycin dose (p < 0.001) and serum creatinine (p = 0.001) with statistical significance, and a multivariable regression model was obtained as follows: Vancomycin serum concentration (mg/l) = -1.296 + 0.281 × vancomycin dose (mg/kg) + 20.458 × serum creatinine (mg/dl) (adjusted coefficient of determination, R = 0.66). This prediction model is expected to contribute to establishing an optimal continuous infusion regimen for vancomycin.
万古霉素是重症监护病房常用的抗生素,患者的肾脏清除率会影响万古霉素的药代动力学特征。已有报道称万古霉素持续静脉输注有诸多优势,但基于患者肾脏清除率的持续给药方案的研究尚不充分。本研究的目的是通过考虑患者的肾脏清除率来建立万古霉素血药浓度预测模型。纳入了2021年7月1日至2022年7月31日在我院住院且有万古霉素持续输注记录的儿童。采用混合效应模型的线性回归分析对性别、年龄、身高、体重、按体重计算的万古霉素剂量、从万古霉素给药开始至治疗药物监测采样时间的间隔以及万古霉素血药浓度进行分析。以万古霉素血药浓度为因变量进行单变量回归分析。结果显示,万古霉素剂量(p < 0.001)和血清肌酐(p = 0.007)是对万古霉素血药浓度影响最大的因素。万古霉素血药浓度受万古霉素剂量(p < 0.001)和血清肌酐(p = 0.001)影响,具有统计学意义,得到多变量回归模型如下:万古霉素血药浓度(mg/l)= -1.296 + 0.281×万古霉素剂量(mg/kg)+ 20.458×血清肌酐(mg/dl)(调整决定系数,R = 0.66)。该预测模型有望有助于建立最佳的万古霉素持续输注方案。